PSMAfore III期试验最终总生存与安全性分析:[177Lu]Lu-PSMA-617对比更换雄激素受体通路抑制剂用于未接受紫杉类治疗的转移性去势抵抗性前列腺癌患者
PSMAfore是一项开放标签国际III期试验,将既往一种ARPI治疗后进展且适合更换ARPI的PSMA阳性mCRPC患者1:1随机分配至177Lu-PSMA-617组或更换ARPI(阿比特龙或恩扎卢胺)组(每组234例)。最终总生存分析按意向治疗原则未显示两组统计学显著差异(HR 0.91,95%CI 0.72-1.14,P=0.20),结果可能受ARPI组高交叉率混杂;177Lu-PSMA-617安全性良好,未发现新安全性信号。
要点
- ITT人群总生存:177Lu-PSMA-617组中位24.48个月 vs 更换ARPI组23.13个月,HR 0.91(95%CI 0.72-1.14,P=0.20),未达统计学显著差异。
- ARPI组234例中141例(60.3%)交叉至177Lu-PSMA-617,交叉校正后OS HR为0.59(95%CI 0.38-0.91)。
- 177Lu-PSMA-617组暴露校正的≥3级及严重TEAE发生率均低于ARPI组,口干135/227例(59.5%),贫血62/227例(27.3%)。
核心结论
- 按意向治疗原则,177Lu-PSMA-617组与更换ARPI组的总生存差异未达统计学显著,结果可能受高交叉率混杂。
- 177Lu-PSMA-617的安全性良好,未发现新的安全性信号。
研究设计与样本
- PSMAfore(NCT04689828)为开放标签、国际、III期试验。
- 纳入PSMA阳性mCRPC、既往一种ARPI治疗后进展一次且适合更换ARPI的患者,1:1随机分配至177Lu-PSMA-617组或更换ARPI(阿比特龙或恩扎卢胺)组,每组234例。
- 中心确认影像学进展后允许从更换ARPI组交叉至177Lu-PSMA-617组。
- 终点包括rPFS(主要终点)、OS(关键次要终点)和安全性(次要终点)。
主要发现
- 中位OS为177Lu-PSMA-617组24.48个月(95%CI 19.55-28.94个月)vs 更换ARPI组23.13个月(95%CI 19.61-25.53个月),HR 0.91(95%CI 0.72-1.14,P=0.20)。
- 基于逆概率删失加权模型交叉校正后的OS HR为0.59(95%CI 0.38-0.91)。
- 177Lu-PSMA-617组 vs 更换ARPI组暴露校正的≥3级治疗中出现不良事件发生率分别为60.8 vs 85.1每100患者治疗年,严重治疗中出现不良事件分别为32.5 vs 49.9每100患者治疗年。
- 177Lu-PSMA-617组口干发生135/227例(59.5%;≥3级2/227例),贫血发生62/227例(27.3%;≥3级14/227例)。
- 更换ARPI组234例中141例(60.3%)交叉至177Lu-PSMA-617,占中心确认影像学进展者的75.4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In PSMAfore, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC), with a favourable safety profile, versus a change in androgen receptor pathway inhibitor (ARPI). We report the final overall survival (OS) analysis and updated safety data. PATIENTS AND METHODS: PSMAfore (NCT04689828) was an open-label, international, phase III trial. Patients with prostate-specific membrane antigen (PSMA)-positive mCRPC who had experienced disease progression once on a previous ARPI and were candidates for ARPI change were randomized 1 : 1 to 177Lu-PSMA-617 or ARPI change to abiraterone or enzalutamide. Crossover from ARPI change to 177Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. Endpoints included rPFS (primary), OS (key secondary), and safety (secondary). RESULTS: Patients were randomized to 177Lu-PSMA-617 or ARPI change (n = 234 each): 141/234 participants (60.3%) randomized to ARPI change crossed over (75.4% of those with centrally confirmed radiographic progression). The median OS was 24.48 months [95% confidence interval (CI) 19.55-28.94 months] with 177Lu-PSMA-617 versus 23.13 months (95% CI 19.61-25.53 months) with ARPI change [hazard ratio (HR) 0.91, 95% CI 0.72-1.14, P = 0.20] based on the intention-to-treat (ITT) principle; the crossover-adjusted OS HR by inverse probability of censoring weighting modelling was 0.59 (95% CI 0.38-0.91). For 177Lu-PSMA-617 versus ARPI change, exposure-adjusted incidences of grade ≥3 and serious treatment-emergent adverse events were 60.8 versus 85.1 and 32.5 versus 49.9 per 100 patient-treatment years, respectively. Dry mouth occurred in 135/227 participants (59.5%; 2/227 grade ≥3) and anaemia in 62/227 (27.3%; 14/227 grade ≥3) in the 177Lu-PSMA-617 arm. CONCLUSIONS: OS analyses did not show a statistically significant difference between the 177Lu-PSMA-617 and ARPI arms based on the ITT principle; results were likely confounded by the high rate of crossover. The safety profile of 177Lu-PSMA-617 was favourable with no new safety signals identified.
引用
- Fizazi K, Chi KN, Shore ND, et al. Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025. PMID: 40680993. doi:10.1016/j.annonc.2025.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。